Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The pharmacology of tacrine at N -methyl- d -aspartate receptors
Martin Hořák, Kristína Holubová, Eugenie Nepovimová, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 75, pp. 54-62
Closed Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease
Kushal Kumar, Ashwani Kumar, Richard M. Keegan, et al.
Biomedicine & Pharmacotherapy (2017) Vol. 98, pp. 297-307
Closed Access | Times Cited: 132
A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease
Yash Pal Singh, Himanshu Rai, Gourav Singh, et al.
European Journal of Medicinal Chemistry (2021) Vol. 215, pp. 113278-113278
Closed Access | Times Cited: 77
Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives
Natália Moreira, Jéssica Ellen Barbosa de Freitas Lima, Marcelo Fiori Marchiori, et al.
Journal of Alzheimer s Disease Reports (2022) Vol. 6, Iss. 1, pp. 177-193
Open Access | Times Cited: 57
Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition
Anna Misiachna, Barbora Svobodová, Jakub Netolický, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116130-116130
Open Access | Times Cited: 8
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease
Vendula Hepnarová, Jan Korábečný, Lenka Matoušková, et al.
European Journal of Medicinal Chemistry (2018) Vol. 150, pp. 292-306
Closed Access | Times Cited: 64
Profiling donepezil template into multipotent hybrids with antioxidant properties
Eva Mezeiová, Katarína Špilovská, Eugenie Nepovimová, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2018) Vol. 33, Iss. 1, pp. 583-606
Open Access | Times Cited: 59
Selective Secretase Targeting for Alzheimer’s Disease Therapy
Alvaro Miranda, Enrique Montiel, Henning Ulrich, et al.
Journal of Alzheimer s Disease (2021) Vol. 81, Iss. 1, pp. 1-17
Closed Access | Times Cited: 51
Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease
Eva Mezeiová, Lukáš Prchal, Martina Hrabinová, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116399-116399
Open Access | Times Cited: 5
Newly Developed Drugs for Alzheimer’s Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission
Jan Korábečný, Eugenie Nepovimová, Tereza Cikánková, et al.
Neuroscience (2017) Vol. 370, pp. 191-206
Closed Access | Times Cited: 57
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)
Hazem Ahmed, Ahmed Haider, Simon M. Ametamey
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 10, pp. 743-767
Closed Access | Times Cited: 45
Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
Giambattista Marotta, Filippo Basagni, Michela Rosini, et al.
Molecules (2020) Vol. 25, Iss. 17, pp. 4005-4005
Open Access | Times Cited: 39
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Karolina Maciejewska, Kamila Czarnecka, Paweł Szymański
Pharmacological Reports (2021) Vol. 73, Iss. 6, pp. 1565-1581
Open Access | Times Cited: 37
Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential
Saikat Mitra, Maniza Muni, Nusrat Jahan Shawon, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-22
Open Access | Times Cited: 27
Combining Deep Learning and Structural Modeling to Identify Potential Acetylcholinesterase Inhibitors from Hericium erinaceus
Thana Sutthibutpong, Kewalin Posansee, Monrudee Liangruksa, et al.
ACS Omega (2024) Vol. 9, Iss. 14, pp. 16311-16321
Open Access | Times Cited: 5
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 4
Prophylaxis by a reversible cholinesterase inhibitor and the treatment NMDA receptor antagonists as combinatorial countermeasure against nerve agent poisoning in mice model
Jiřı́ Kassa, Jan Konečný, Barbora Svobodová, et al.
Chemico-Biological Interactions (2025) Vol. 407, pp. 111386-111386
Closed Access
Donepezil-Based Rational Design of N-Substituted Quinazolinthioacetamide Candidates as Potential Acetylcholine Esterase Inhibitors for the Treatment of Alzheimer’s Disease: In vitro and In vivo Studies
Ahmed A. Al‐Karmalawy, Ahmed F. Mohamed, Heba Nasr Shalaby, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Screening novel drug candidates for Alzheimer’s disease by an integrated network and transcriptome analysis
Yonglin Peng, Meng Yuan, Juncai Xin, et al.
Bioinformatics (2020) Vol. 36, Iss. 17, pp. 4626-4632
Closed Access | Times Cited: 35
Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease
Yao Chen, Jie Zhu, Jun Mo, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2017) Vol. 33, Iss. 1, pp. 290-302
Open Access | Times Cited: 34
Pro-cognitive effects of dual tacrine derivatives acting as cholinesterase inhibitors and NMDA receptor antagonists
Markéta Chvojková, David Kolář, Katarina Kovacova, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116821-116821
Open Access | Times Cited: 3
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer’s disease
Xin Lü, Siyu He, Qi Li, et al.
Bioorganic & Medicinal Chemistry (2018) Vol. 26, Iss. 8, pp. 1665-1674
Closed Access | Times Cited: 31
A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer’s Disease
Jan Korábečný, Katarína Špilovská, Eva Mezeiová, et al.
Current Medicinal Chemistry (2018) Vol. 26, Iss. 30, pp. 5625-5648
Closed Access | Times Cited: 31
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy
Eva Mezeiová, Jan Korábečný, Vendula Šepsová, et al.
Molecules (2017) Vol. 22, Iss. 8, pp. 1265-1265
Open Access | Times Cited: 30
7-Methoxyderivative of tacrine is a ‘foot-in-the-door’ open-channel blocker of GluN1/GluN2 and GluN1/GluN3 NMDA receptors with neuroprotective activity in vivo
Martina Kaniaková, Lenka Kletečková, Katarína Lichnerová, et al.
Neuropharmacology (2018) Vol. 140, pp. 217-232
Closed Access | Times Cited: 30
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors
Barbora Svobodová, Eva Mezeiová, Vendula Hepnarová, et al.
Biomolecules (2019) Vol. 9, Iss. 8, pp. 379-379
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top